Welcome to our dedicated page for Sio Gene Therapies news (Ticker: SIOX), a resource for investors and traders seeking the latest updates and insights on Sio Gene Therapies stock.
Sio Gene Therapies Inc. (SIOX) was a clinical-stage biopharmaceutical company focused on developing gene therapies for neurological disorders before ceasing operations in 2022. This page serves as the definitive source for official updates regarding the company's dissolution process and stockholder distributions.
Investors and stakeholders will find verified information about liquidating distributions, stock transfer limitations, and regulatory timelines under Delaware law. All content is curated from official SEC filings and corporate announcements to ensure accuracy.
The resource covers key developments including the initial $0.435 per share distribution, retention of $7.2 million for dissolution expenses, and potential subsequent payments. Updates will reflect material events through the three-year dissolution period mandated by DGCL.
Bookmark this page for streamlined access to critical updates about SIOX's corporate wind-down. While stock transfers are discontinued, stakeholders should monitor this page for official communications regarding remaining distributions and dissolution milestones.
Sio Gene Therapies Inc. (SIOX) has completed enrollment of eight Type II patients in the dose-escalation study of AXO-AAV-GM1 for GM1 gangliosidosis. The company is set to report 12-month topline data in late Q3 or early Q4 2021. As of June 30, 2021, Sio held $111 million in cash, providing a runway into Q4 2022. In Q1 2021, R&D expenses rose to $8.1 million due to clinical trial costs, with a net loss of $11.9 million. Despite increased expenses, Sio is optimistic about its clinical trials and FDA discussions planned for 2022.
Sio Gene Therapies Inc. (NASDAQ: SIOX) reported robust financial results for the fiscal year ending March 31, 2021, highlighting a strong cash position of $119 million. The company anticipates significant milestones in FY2021 for its GM1 gangliosidosis program, including a 12-month data update and a regulatory meeting with the FDA. Research and development expenses dropped to $24.9 million, down $22.2 million year-over-year. The net loss for the year was $32.4 million, improved from $72.6 million the previous year, indicating financial stability and progress towards commercialization.
Sio Gene Therapies (NASDAQ: SIOX), focused on gene therapies for neurodegenerative diseases, will present at the UBS Global Healthcare Virtual Conference on May 24, 2021. The company aims to improve patient lives through innovative genetic medicines targeting conditions like GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases. The presentation will be led by CEO Pavan Cheruvu at 10:00 AM ET. More details are available via a webcast.
Sio Gene Therapies Inc. (NASDAQ: SIOX) announced promising results from its AXO-AAV-GM1 gene therapy for GM1 gangliosidosis. In a Phase 1/2 trial, 4 out of 5 children showed a reduction in GM1 ganglioside levels in cerebrospinal fluid at the 6-month mark. The therapy demonstrated safety and a favorable profile, with no serious adverse events reported. Positive clinical stabilization was observed in all five children. The company is on track to report further safety and efficacy data at the 12-month follow-up in 2H 2021.
Sio Gene Therapies Inc. (NASDAQ: SIOX) announced four oral presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy, scheduled from May 11-14, 2021. These include data on AXO-AAV-GM1 for GM1 gangliosidosis and AXO-Lenti-PD for Parkinson's disease. Dr. Cynthia Tifft will discuss safety and efficacy data for the AXO-AAV-GM1 gene therapy, while other presentations will cover biomarker data and safety studies. Sio's gene therapies aim to transform treatment for neurodegenerative diseases, receiving Orphan Drug and Rare Pediatric Disease Designations.
Sio Gene Therapies Inc. (NASDAQ: SIOX) announced participation in multiple upcoming investor and scientific conferences in April 2021, focusing on gene therapies for neurodegenerative diseases. Key events include Guggenheim's Healthcare Talks on April 1, featuring a panel on CNS indications, and the Alliance for Regenerative Medicine conference on April 6, discussing commercialization in advanced therapies. Additionally, Sio will present on GM1 and GM2 gangliosidosis during NTSAD’s conference on April 23. These efforts reflect Sio's commitment to advancing gene therapies for conditions like Tay-Sachs and Parkinson's disease.
Sio Gene Therapies (NASDAQ: SIOX) announced it had $120.9 million in cash as of March 12, 2021, boosted by a $15 million equity investment from Suvretta Capital. Since December 2020, the company raised $49.1 million, including $37.1 million from stock sales. Expected milestone payments include $4.8 million upon marketing approval of cenobamate. The firm believes its cash position will fund major upcoming milestones for its AXO-AAV-GM1 gene therapy program, including data releases in 2021 and 2022, and aims to lead gene therapy trials in GM1 gangliosidosis.
Sio Gene Therapies Inc. (NASDAQ: SIOX), focused on gene therapies for neurodegenerative diseases, will participate in several upcoming investor and scientific conferences.
- Oppenheimer Conference: Presentation on March 17, 2021, at 2:30 PM ET by Gavin Corcoran.
- Redburn Gene Therapy Summit: Panel discussion on March 31, 2021, at 8:00 AM ET led by Parag V. Meswani.
- Guggenheim Healthcare Talks: 1-on-1 investor meetings on April 1, 2021.
- Gene Therapy Patient Engagement Summit: March 23-25, 2021.
The company aims to radically improve lives through innovative genetic medicines.
Sio Gene Therapies Inc. (NASDAQ: SIOX), focused on gene therapies for neurodegenerative diseases, will present at the 10th Annual SVB Leerink Global Healthcare Conference from February 22-26, 2021. The presentation is scheduled for February 24, 2021, at 1:40 PM ET, featuring CEO Pavan Cheruvu in a fireside chat format. Additionally, the company management will engage in one-on-one investor meetings during the event. Sio Gene Therapies aims to develop potentially curative therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, while also targeting prevalent conditions like Parkinson's disease.
Sio Gene Therapies Inc. (NASDAQ: SIOX) reported financial results for its third fiscal quarter ended December 31, 2020. The net loss was $10.5 million, or $0.20 per share, a reduction from $14.0 million or $0.62 per share in the prior year. Research and development expenses decreased to $6.4 million, down from $8.3 million. The company had $81 million in cash and expects to receive an additional $16 million from Arvelle Therapeutics shares, sustaining its cash runway into Q2 2022. Advances in gene therapies for neurodegenerative diseases were highlighted, with ongoing clinical trials showing promising results.
FAQ
What is the market cap of Sio Gene Therapies (SIOX)?
